+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gene Editing Market Size, Share & Trends Analysis Report by Product & Service, Technology, End-user, Region, and Segment Forecasts, 2026-2033

  • PDF Icon

    Report

  • 120 Pages
  • January 2026
  • Region: Global
  • Grand View Research
  • ID: 6227948
The global gene editing market size was estimated at USD 5.87 billion in 2025 and is projected to reach USD 18.55 billion by 2033, growing at a CAGR of 15.71% from 2026 to 2033. This growth is supported by rising adoption of advanced gene therapies, increasing investments in biopharmaceutical research, and growing demand for precision medicine.

Growing demand for curative genetic therapies

The increasing need for precision medicine in rare and genetic disorders is one of the main factors driving the gene editing market, as health care systems are increasingly inclined to shift from symptomatic management to more targeted, root-cause interventions. Many rare diseases are monogenic, making them appropriate candidates for gene-editing techniques that can directly fix, silence, or alter the defective genes. The customary chronic treatment approaches often entail lifelong prescription of medicines with limited effect. However, gene editing opens the door to either single or very rare interventions with lasting results.

The developers need much more than basic editing tools. They need to perform mutation-specific programs with advanced editing enzymes, guide RNA design, delivery optimization, and robust analytical validation. As a result, there has been a continuous demand for gene-editing reagents, GMP-grade components, and specialized contract research and manufacturing services. The combination of the above factors, namely unmet clinical need, precision-focused healthcare strategies, and scalable platform development, has made gene editing a critical growth engine in the next generation of therapeutic innovations.

Global Gene Editing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global gene editing market report based on product & service, technology, end-user, and region:

Product & Service Outlook (Revenue, USD Billion, 2021-2033)

  • Reagents and Consumables
  • Software and Systems
  • Services

Technology Outlook (Revenue, USD Billion, 2021-2033)

  • CRISPR-Cas System
  • Transcription Activator-Like Effector Nucleases (TALENs)
  • Zinc Finger Nucleases (ZFNs)
  • Meganucleases/Homing Endonucleases

End-user Outlook (Revenue, USD Billion, 2021-2033)

  • Biotechnology and Pharmaceutical Companies
  • University and Research Institutes
  • Other End-users

Regional Outlook (Revenue, USD Billion, 2021-2033)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product & Service
1.2.2. Technology
1.2.3. End User
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Gene Editing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Demand For Curative Genetic Therapies
3.2.1.2. Expansion Of Enabling Ecosystem
3.2.2. Market Restraint Analysis
3.2.2.1. Capital-Intensive Development Pathways
3.2.2.2. Fragmented Regulatory Landscape
3.2.3. Market Opportunity Analysis
3.2.3.1. Monetization Beyond Therapeutic Products
3.2.3.2. Broadening Application Spectrum
3.2.4. Market Challenge Analysis
3.2.4.1. Limitations In Targeted In Vivo Delivery
3.2.4.2. Complex Intellectual Property Environment
3.2.5. Key Partnerships & Collaborations
3.2.6. Patent Analysis
3.2.7. Funding & Investment Landscape
3.3. Industry Analysis Tools
3.3.1. SWOT Analysis
3.3.2. PESTEL Analysis
3.3.3. Porter’s Analysis
Chapter 4. Gene Editing Market: Product & Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Product & Service Market Share, 2025 & 2033
4.3. Reagents and Consumables
4.3.1. Reagents and Consumables Market Estimates and Forecasts 2021 to 2033 (USD million)
4.4. Software and Systems
4.4.1. Software and Systems Market Estimates and Forecasts 2021 to 2033 (USD million)
4.5. Services
4.5.1. Services Market Estimates and Forecasts 2021 to 2033 (USD million)
Chapter 5. Gene Editing Market: Technology Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Technology Market Share, 2025 & 2033
5.3. CRISPR-Cas System
5.3.1. CRISPR-Cas System Market Estimates and Forecasts 2021 to 2033 (USD million)
5.4. Transcription Activator-Like Effector Nucleases (TALENs)
5.4.1. Transcription Activator-Like Effector Nucleases (TALENs) Market Estimates and Forecasts 2021 to 2033 (USD million)
5.5. Zinc Finger Nucleases (ZFNs)
5.5.1. Zinc Finger Nucleases (ZFNs) Market Estimates and Forecasts 2021 to 2033 (USD million)
5.6. Meganucleases/Homing Endonucleases
5.6.1. Meganucleases/Homing Endonucleases Market Estimates and Forecasts 2021 to 2033 (USD million)
5.7. Technology Landscape and Competitive Insights
Chapter 6. Gene Editing Market: End User Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. End User Market Share, 2025 & 2033
6.3. Biotechnology and Pharmaceutical Companies
6.3.1. Biotechnology and Pharmaceutical Companies Market Estimates and Forecasts 2021 to 2033 (USD million)
6.4. University and Research Institutes
6.4.1. University and Research Institutes Market Estimates and Forecasts 2021 to 2033 (USD million)
6.5. Other End Users
6.5.1. Other End Users Market Estimates and Forecasts 2021 to 2033 (USD million)
Chapter 7. Gene Editing Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2025 & 2033
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. U.S.
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework
7.4.1.3. Reimbursement environment
7.4.1.4. Growth drivers
7.4.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
7.4.2. Canada
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework
7.4.2.3. Reimbursement environment
7.4.2.4. Growth drivers
7.4.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
7.4.3. Mexico
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework
7.4.3.3. Reimbursement environment
7.4.3.4. Growth drivers
7.4.3.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Europe
7.5.1. UK
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework
7.5.1.3. Reimbursement environment
7.5.1.4. Growth drivers
7.5.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
7.5.2. Germany
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Reimbursement environment
7.5.2.4. Growth drivers
7.5.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
7.5.3. France
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Reimbursement environment
7.5.3.4. Growth drivers
7.5.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
7.5.4. Italy
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Reimbursement environment
7.5.4.4. Growth drivers
7.5.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
7.5.5. Spain
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework
7.5.5.3. Reimbursement environment
7.5.5.4. Growth drivers
7.5.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
7.5.6. Norway
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework
7.5.6.3. Reimbursement environment
7.5.6.4. Growth drivers
7.5.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
7.5.7. Sweden
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework
7.5.7.3. Reimbursement environment
7.5.7.4. Growth drivers
7.5.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
7.5.8. Denmark
7.5.8.1. Key country dynamics
7.5.8.2. Regulatory framework
7.5.8.3. Reimbursement environment
7.5.8.4. Growth drivers
7.5.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework
7.6.1.3. Reimbursement environment
7.6.1.4. Growth drivers
7.6.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
7.6.2. China
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Reimbursement environment
7.6.2.4. Growth drivers
7.6.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
7.6.3. India
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Reimbursement environment
7.6.3.4. Growth drivers
7.6.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
7.6.4. Australia
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Reimbursement environment
7.6.4.4. Growth drivers
7.6.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
7.6.5. South Korea
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Reimbursement environment
7.6.5.4. Growth drivers
7.6.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
7.6.6. Thailand
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Reimbursement environment
7.6.6.4. Growth drivers
7.6.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework
7.7.1.3. Reimbursement environment
7.7.1.4. Growth drivers
7.7.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
7.7.2. Argentina
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Reimbursement environment
7.7.2.4. Growth drivers
7.7.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework
7.8.1.3. Reimbursement environment
7.8.1.4. Growth drivers
7.8.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
7.8.2. Saudi Arabia
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Reimbursement environment
7.8.2.4. Growth drivers
7.8.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.8.3. UAE
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Reimbursement environment
7.8.3.4. Growth drivers
7.8.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.8.4. Kuwait
7.8.4.1. Key country dynamics
7.8.4.2. Regulatory framework
7.8.4.3. Reimbursement environment
7.8.4.4. Growth drivers
7.8.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Global Competitive Landscape
8.1. Global Market Position Analysis, 2025
Chapter 9. North America Competitive Landscape
9.1. Company Profiles
9.1.1. Thermo Fisher Scientific Inc.
9.1.1.1. Company overview
9.1.1.2. Financial performance
9.1.1.3. Product benchmarking
9.1.1.4. Strategic initiatives
9.1.2. Revvity
9.1.2.1. Company overview
9.1.2.2. Financial performance
9.1.2.3. Product benchmarking
9.1.2.4. Strategic initiatives
9.1.3. Danaher
9.1.3.1. Company overview
9.1.3.2. Financial performance
9.1.3.3. Product benchmarking
9.1.3.4. Strategic initiatives
9.1.4. Intellia Therapeutics
9.1.4.1. Company overview
9.1.4.2. Financial performance
9.1.4.3. Product benchmarking
9.1.4.4. Strategic initiatives
9.1.5. Sangamo Therapeutics
9.1.5.1. Company overview
9.1.5.2. Financial performance
9.1.5.3. Product benchmarking
9.1.5.4. Strategic initiatives
9.1.6. Beam Therapeutics
9.1.6.1. Company overview
9.1.6.2. Financial performance
9.1.6.3. Product benchmarking
9.1.6.4. Strategic initiatives
9.1.7. Illumina, Inc.
9.1.7.1. Company overview
9.1.7.2. Financial performance
9.1.7.3. Product benchmarking
9.1.7.4. Strategic initiatives
9.1.8. Editas Medicine
9.1.8.1. Company overview
9.1.8.2. Financial performance
9.1.8.3. Product benchmarking
9.1.8.4. Strategic initiatives
9.1.9. Synthego
9.1.9.1. Company overview
9.1.9.2. Financial performance
9.1.9.3. Product benchmarking
9.1.9.4. Strategic initiatives
Chapter 10. Europe Competitive Landscape
10.1. Company Profiles
10.1.1. Merck KGaA
10.1.1.1. Company overview
10.1.1.2. Financial performance
10.1.1.3. Product benchmarking
10.1.1.4. Strategic initiatives
10.1.2. QIAGEN
10.1.2.1. Company overview
10.1.2.2. Financial performance
10.1.2.3. Product benchmarking
10.1.2.4. Strategic initiatives
10.1.3. Cellectis S.A.
10.1.3.1. Company overview
10.1.3.2. Financial performance
10.1.3.3. Product benchmarking
10.1.3.4. Strategic initiatives
10.1.4. CRISPR Therapeutics
10.1.4.1. Company overview
10.1.4.2. Financial performance
10.1.4.3. Product benchmarking
10.1.4.4. Strategic initiatives
10.1.5. Vivlion GmbH
10.1.5.1. Company overview
10.1.5.2. Financial performance
10.1.5.3. Product benchmarking
10.1.5.4. Strategic initiatives
10.1.6. Eurofins Genomics
10.1.6.1. Company overview
10.1.6.2. Financial performance
10.1.6.3. Product benchmarking
10.1.6.4. Strategic initiatives
10.1.7. AMSBIO
10.1.7.1. Company overview
10.1.7.2. Financial performance
10.1.7.3. Product benchmarking
10.1.7.4. Strategic initiatives
10.1.8. OZ Biosciences
10.1.8.1. Company overview
10.1.8.2. Financial performance
10.1.8.3. Product benchmarking
10.1.8.4. Strategic initiatives
Chapter 11. Asia Pacific Competitive Landscape
11.1. Company Profiles
11.1.1. GenScript
11.1.1.1. Company overview
11.1.1.2. Financial performance
11.1.1.3. Product benchmarking
11.1.1.4. Strategic initiatives
11.1.2. Takara Bio
11.1.2.1. Company overview
11.1.2.2. Financial performance
11.1.2.3. Product benchmarking
11.1.2.4. Strategic initiatives
11.1.3. Macrogen, Inc.
11.1.3.1. Company overview
11.1.3.2. Financial performance
11.1.3.3. Product benchmarking
11.1.3.4. Strategic initiatives
11.1.4. BRL MEDICINE
11.1.4.1. Company overview
11.1.4.2. Financial performance
11.1.4.3. Product benchmarking
11.1.4.4. Strategic initiatives
11.1.5. Biocytogen
11.1.5.1. Company overview
11.1.5.2. Financial performance
11.1.5.3. Product benchmarking
11.1.5.4. Strategic initiatives
11.1.6. BGI Genomics
11.1.6.1. Company overview
11.1.6.2. Financial performance
11.1.6.3. Product benchmarking
11.1.6.4. Strategic initiatives
11.1.7. Bioneer
11.1.7.1. Company overview
11.1.7.2. Financial performance
11.1.7.3. Product benchmarking
11.1.7.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America gene editing market, by region, 2021-2033 (USD Million)
Table 3 North America gene editing market, by product & service, 2021-2033 (USD Million)
Table 4 North America gene editing market, by technology, 2021-2033 (USD Million)
Table 5 North America gene editing market, by end user, 2021-2033 (USD Million)
Table 6 U.S. gene editing market, by product & service, 2021-2033 (USD Million)
Table 7 U.S. gene editing market, by technology, 2021-2033 (USD Million)
Table 8 U.S. gene editing market, by end user, 2021-2033 (USD Million)
Table 9 Mexico gene editing market, by product & service, 2021-2033 (USD Million)
Table 10 Mexico gene editing market, by technology, 2021-2033 (USD Million)
Table 11 Mexico gene editing market, by end user, 2021-2033 (USD Million)
Table 12 Canada gene editing market, by product & service, 2021-2033 (USD Million)
Table 13 Canada gene editing market, by technology, 2021-2033 (USD Million)
Table 14 Canada gene editing market, by end user, 2021-2033 (USD Million)
Table 15 Europe gene editing market, by region, 2021-2033 (USD Million)
Table 16 Europe gene editing market, by product & service, 2021-2033 (USD Million)
Table 17 Europe gene editing market, by technology, 2021-2033 (USD Million)
Table 18 Europe gene editing market, by end user, 2021-2033 (USD Million)
Table 19 Germany gene editing market, by product & service, 2021-2033 (USD Million)
Table 20 Germany gene editing market, by technology, 2021-2033 (USD Million)
Table 21 Germany gene editing market, by end user, 2021-2033 (USD Million)
Table 22 UK gene editing market, by product & service, 2021-2033 (USD Million)
Table 23 UK gene editing market, by technology, 2021-2033 (USD Million)
Table 24 UK gene editing market, by end user, 2021-2033 (USD Million)
Table 25 France gene editing market, by product & service, 2021-2033 (USD Million)
Table 26 France gene editing market, by technology, 2021-2033 (USD Million)
Table 27 France gene editing market, by end user, 2021-2033 (USD Million)
Table 28 Italy gene editing market, by product & service, 2021-2033 (USD Million)
Table 29 Italy gene editing market, by technology, 2021-2033 (USD Million)
Table 30 Italy gene editing market, by end user, 2021-2033 (USD Million)
Table 31 Spain gene editing market, by product & service, 2021-2033 (USD Million)
Table 32 Spain gene editing market, by technology, 2021-2033 (USD Million)
Table 33 Spain gene editing market, by end user, 2021-2033 (USD Million)
Table 34 Denmark gene editing market, by product & service, 2021-2033 (USD Million)
Table 35 Denmark gene editing market, by technology, 2021-2033 (USD Million)
Table 36 Denmark gene editing market, by end user, 2021-2033 (USD Million)
Table 37 Sweden gene editing market, by product & service, 2021-2033 (USD Million)
Table 38 Sweden gene editing market, by technology, 2021-2033 (USD Million)
Table 39 Sweden gene editing market, by end user, 2021-2033 (USD Million)
Table 40 Norway gene editing market, by product & service, 2021-2033 (USD Million)
Table 41 Norway gene editing market, by technology, 2021-2033 (USD Million)
Table 42 Norway gene editing market, by end user, 2021-2033 (USD Million)
Table 43 Asia Pacific gene editing market, by region, 2021-2033 (USD Million)
Table 44 Asia Pacific gene editing market, by product & service, 2021-2033 (USD Million)
Table 45 Asia Pacific gene editing market, by technology, 2021-2033 (USD Million)
Table 46 Asia Pacific gene editing market, by end user, 2021-2033 (USD Million)
Table 47 China gene editing market, by product & service, 2021-2033 (USD Million)
Table 48 China gene editing market, by technology, 2021-2033 (USD Million)
Table 49 China gene editing market, by end user, 2021-2033 (USD Million)
Table 50 Japan gene editing market, by product & service, 2021-2033 (USD Million)
Table 51 Japan gene editing market, by technology, 2021-2033 (USD Million)
Table 52 Japan gene editing market, by end user, 2021-2033 (USD Million)
Table 53 India gene editing market, by product & service, 2021-2033 (USD Million)
Table 54 India gene editing market, by technology, 2021-2033 (USD Million)
Table 55 India gene editing market, by end user, 2021-2033 (USD Million)
Table 56 South Korea gene editing market, by product & service, 2021-2033 (USD Million)
Table 57 South Korea gene editing market, by technology, 2021-2033 (USD Million)
Table 58 South Korea gene editing market, by end user, 2021-2033 (USD Million)
Table 59 Australia gene editing market, by product & service, 2021-2033 (USD Million)
Table 60 Australia gene editing market, by technology, 2021-2033 (USD Million)
Table 61 Australia gene editing market, by end user, 2021-2033 (USD Million)
Table 62 Thailand gene editing market, by product & service, 2021-2033 (USD Million)
Table 63 Thailand gene editing market, by technology, 2021-2033 (USD Million)
Table 64 Thailand gene editing market, by end user, 2021-2033 (USD Million)
Table 65 Latin America gene editing market, by product & service, 2021-2033 (USD Million)
Table 66 Latin America gene editing market, by technology, 2021-2033 (USD Million)
Table 67 Latin America gene editing market, by end user, 2021-2033 (USD Million)
Table 68 Brazil gene editing market, by product & service, 2021-2033 (USD Million)
Table 69 Brazil gene editing market, by technology, 2021-2033 (USD Million)
Table 70 Brazil gene editing market, by end user, 2021-2033 (USD Million)
Table 71 Argentina gene editing market, by product & service, 2021-2033 (USD Million)
Table 72 Argentina gene editing market, by technology, 2021-2033 (USD Million)
Table 73 Argentina gene editing market, by end user, 2021-2033 (USD Million)
Table 74 MEA gene editing market, by region, 2021-2033 (USD Million)
Table 75 MEA gene editing market, by product & service, 2021-2033 (USD Million)
Table 76 MEA gene editing market, by technology, 2021-2033 (USD Million)
Table 77 MEA gene editing market, by end user, 2021-2033 (USD Million)
Table 78 South Africa gene editing market, by product & service, 2021-2033 (USD Million)
Table 79 South Africa gene editing market, by technology, 2021-2033 (USD Million)
Table 80 South Africa gene editing market, by end user, 2021-2033 (USD Million)
Table 81 Saudi Arabia gene editing market, by product & service, 2021-2033 (USD Million)
Table 82 Saudi Arabia gene editing market, by technology, 2021-2033 (USD Million)
Table 83 Saudi Arabia gene editing market, by end user, 2021-2033 (USD Million)
Table 84 UAE gene editing market, by product & service, 2021-2033 (USD Million)
Table 85 UAE gene editing market, by technology, 2021-2033 (USD Million)
Table 86 UAE gene editing market, by end user, 2021-2033 (USD Million)
Table 87 Kuwait gene editing market, by product & service, 2021-2033 (USD Million)
Table 88 Kuwait gene editing market, by technology, 2021-2033 (USD Million)
Table 89 Kuwait gene editing market, by end user, 2021-2033 (USD Million)
List of Figures
Figure 1 Gene editing market segmentation
Figure 2 Data analysis models
Figure 3 Market formulation and validation
Figure 4 Data validating & publishing
Figure 5 Market research process
Figure 6 Information procurement
Figure 7 Primary research
Figure 8 Value-chain-based sizing & forecasting
Figure 9 QFD modelling for market share assessment
Figure 10 Market formulation & validation
Figure 11 Commodity flow analysis
Figure 12 Market outlook
Figure 13 Segment snapshot-1
Figure 14 Segment snapshot-2
Figure 15 Competitive landscape snapshot
Figure 16 Gene editing market value, 2025 (USD billion)
Figure 17 Market trends & outlook
Figure 18 Market dynamics
Figure 19 SWOT analysis
Figure 20 PESTEL analysis
Figure 21 PORTER’s analysis
Figure 22 Gene editing market: Product & service outlook key takeaways
Figure 23 Gene editing market: Product & service movement analysis
Figure 24 Reagents and consumables market estimates and forecasts, 2021-2033 (USD Million)
Figure 25 Software and systems market estimates and forecasts, 2021-2033 (USD Million)
Figure 26 Services market estimates and forecasts, 2021-2033 (USD Million)
Figure 27 Gene editing market: Technology outlook key takeaways
Figure 28 Gene editing market: Technology movement analysis
Figure 29 CRISPR-Cas system market estimates and forecasts, 2021-2033 (USD Million)
Figure 30 Transcription activator-like effector nucleases (TALENs) market estimates and forecasts, 2021-2033 (USD Million)
Figure 31 Zinc finger nucleases market estimates and forecasts, 2021-2033 (USD Million)
Figure 32 Meganucleases/homing endonucleases market estimates and forecasts, 2021-2033 (USD Million)
Figure 33 Gene editing market: End user outlook key takeaways
Figure 34 Gene editing market: End user movement analysis
Figure 35 Biotechnology and pharmaceutical companies market estimates and forecasts, 2021-2033 (USD Million)
Figure 36 University and research institutes market estimates and forecasts, 2021-2033 (USD Million)
Figure 37 Others market estimates and forecasts, 2021-2033 (USD Million)
Figure 38 Regional marketplace outlook, 2025 & 2033 (USD Million)
Figure 39 Regional marketplace: Key takeaways
Figure 40 North America gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 41 Key country dynamics
Figure 42 U.S. gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 43 Key country dynamics
Figure 44 Canada gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 45 Key country dynamics
Figure 46 Mexico gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 47 Europe gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 48 Key country dynamics
Figure 49 Germany gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 50 Key country dynamics
Figure 51 UK gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 52 Key country dynamics
Figure 53 France gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 54 Key country dynamics
Figure 55 Italy gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 56 Key country dynamics
Figure 57 Spain gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 58 Key country dynamics
Figure 59 Denmark gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 60 Key country dynamics
Figure 61 Sweden gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 62 Key country dynamics
Figure 63 Norway gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 64 Asia Pacific gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 65 Key country dynamics
Figure 66 Japan gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 67 Key country dynamics
Figure 68 China gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 69 Key country dynamics
Figure 70 India gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 71 Key country dynamics
Figure 72 South Korea gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 73 Key country dynamics
Figure 74 Australia gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 75 Key country dynamics
Figure 76 Thailand gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 77 Latin America gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 78 Key country dynamics
Figure 79 Brazil gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 80 Key country dynamics
Figure 81 Argentina gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 82 MEA gene editing market estimates and forecast, 2021-2033 (USD Million)
Figure 83 Key country dynamics
Figure 84 South Africa gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 85 Key country dynamics
Figure 86 Saudi Arabia gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 87 Key country dynamics
Figure 88 UAE gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 89 Key country dynamics
Figure 90 Kuwait gene editing market estimates and forecasts, 2021-2033 (USD Million)
Figure 91 Company market position analysis, 2025
Figure 92 Strategic framework - North America
Figure 93 Strategic framework - Europe
Figure 94 Strategic framework - Asia Pacific

Companies Mentioned

The leading players profiled in this Gene Editing market report include:
  • Thermo Fisher Scientific Inc.
  • Revvity
  • Danaher
  • Intellia Therapeutics
  • Sangamo Therapeutics
  • Beam Therapeutics
  • Illumina, Inc.
  • Editas Medicine
  • Synthego

Table Information